@inproceedings{inproceedings, title  = {{Long-term efficacy and safety data for dupilumab in a phase III open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled moderate-to-severe atopic dermatitis}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Cork MJ and Thaci D and Eichenfield L and Arkwright PD and Chen Z and O'Malley JT and Bansal A}},

 volume = {{185}},

 journal = {{BRITISH JOURNAL OF DERMATOLOGY}},

 issue = {{3}},

 pages = {{E115-E116}},

 note = {{Accessed on 2024/12/22}}}